By Andy Batts:
Abiomed (NASDAQ:ABMD) announced RECOVER RIGHT clinical trial results earlier this week. RECOVER RIGHT is an IDE (investigational device exemption) study for the company's Impella RP (right percutaneous) pump, the clinical results of which demonstrated a survival rate of 73% in the overall patient population. Michael R. Minogue, Abiomed's Chairman, President and CEO, said, "The Impella RP is the first percutaneous, single vascular access pump designed for right heart support. The pump is designed to be used concurrently with other left ventricle pumps in the Impella platform, which in the future may offer physicians the option of percutaneous biventricular support for acute patients."
The primary endpoint of study was survival rate of patients at 30 days, and hospital discharge, or bridge to the next therapy. Overall, the survival rate was 73% in the entire population at 30 days, as mentioned above, and Cohort A had a survival rate of 83.3% and
Complete Story ยป